Cargando…
Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 chi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712465/ https://www.ncbi.nlm.nih.gov/pubmed/36177517 http://dx.doi.org/10.1002/epi4.12653 |
_version_ | 1784841794222030848 |
---|---|
author | Li, Yue Dong, Na Qin, Yu‐Xin Dai, Hao‐Ran Hu, Ya‐Hui Zhao, Yue‐Tao Guo, Hong‐Li Zhang, Yuan‐Yuan Chen, Jing Lu, Xiao‐Peng Chen, Feng |
author_facet | Li, Yue Dong, Na Qin, Yu‐Xin Dai, Hao‐Ran Hu, Ya‐Hui Zhao, Yue‐Tao Guo, Hong‐Li Zhang, Yuan‐Yuan Chen, Jing Lu, Xiao‐Peng Chen, Feng |
author_sort | Li, Yue |
collection | PubMed |
description | OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 children were analyzed for routine therapeutic drug monitoring (TDM) between 2021 and 2022. We retrospectively reviewed the clinical data of these patients and assessed the efficacy at 3 months after treatment initiation. Trough concentration‐to‐dose ratio (C (0)/Dose ratio) of PER was compared among patients on various potential influencing factors. RESULTS: A 3‐month PER therapy produced a ≥50% reduction in seizure frequency in 58.8% of patients. Twelve patients reported at least one adverse effect (AE), mainly dizziness. The monitoring data showed that the median C (0) was 325.5 ng/mL. Under maintenance dosages, approximately 75% of the C (0) values were 180.0‐610.0 ng/mL. The C (0)/Dose ratio in patients aged 1 to <4 was significantly lower by twofold than in those aged 4 to ≤12 years (P = 0.001). Enzyme‐inducing ASMs (EIASMs) decreased the C (0)/Dose ratio of PER by 25.9% (P = 0.165). In addition, seizure frequency reduction in responders was achieved at a median PER C (0) value of 357 ng/mL, which was similar to the value of 314 ng/mL found in nonresponders (P = 0.288). No significant difference was found in PER C (0) values between patients with and without AEs (P = 0.082). SIGNIFICANCE: In this study, PER treatment showed acceptable efficacy and tolerance in Chinese children with epilepsy. Contributing factors like age to variable C (0)/Dose ratios were identified, and complex PER‐ASMs interactions were observed. Notably, the reference range, that is, 180.0‐610.0 ng/mL, for routine PER monitoring may be more applicable for them. Routine TDM should be considered a positive attempt to manage the effectiveness and safety of PER. |
format | Online Article Text |
id | pubmed-9712465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97124652022-12-02 Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio Li, Yue Dong, Na Qin, Yu‐Xin Dai, Hao‐Ran Hu, Ya‐Hui Zhao, Yue‐Tao Guo, Hong‐Li Zhang, Yuan‐Yuan Chen, Jing Lu, Xiao‐Peng Chen, Feng Epilepsia Open Original Articles OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 children were analyzed for routine therapeutic drug monitoring (TDM) between 2021 and 2022. We retrospectively reviewed the clinical data of these patients and assessed the efficacy at 3 months after treatment initiation. Trough concentration‐to‐dose ratio (C (0)/Dose ratio) of PER was compared among patients on various potential influencing factors. RESULTS: A 3‐month PER therapy produced a ≥50% reduction in seizure frequency in 58.8% of patients. Twelve patients reported at least one adverse effect (AE), mainly dizziness. The monitoring data showed that the median C (0) was 325.5 ng/mL. Under maintenance dosages, approximately 75% of the C (0) values were 180.0‐610.0 ng/mL. The C (0)/Dose ratio in patients aged 1 to <4 was significantly lower by twofold than in those aged 4 to ≤12 years (P = 0.001). Enzyme‐inducing ASMs (EIASMs) decreased the C (0)/Dose ratio of PER by 25.9% (P = 0.165). In addition, seizure frequency reduction in responders was achieved at a median PER C (0) value of 357 ng/mL, which was similar to the value of 314 ng/mL found in nonresponders (P = 0.288). No significant difference was found in PER C (0) values between patients with and without AEs (P = 0.082). SIGNIFICANCE: In this study, PER treatment showed acceptable efficacy and tolerance in Chinese children with epilepsy. Contributing factors like age to variable C (0)/Dose ratios were identified, and complex PER‐ASMs interactions were observed. Notably, the reference range, that is, 180.0‐610.0 ng/mL, for routine PER monitoring may be more applicable for them. Routine TDM should be considered a positive attempt to manage the effectiveness and safety of PER. John Wiley and Sons Inc. 2022-10-12 /pmc/articles/PMC9712465/ /pubmed/36177517 http://dx.doi.org/10.1002/epi4.12653 Text en © 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Li, Yue Dong, Na Qin, Yu‐Xin Dai, Hao‐Ran Hu, Ya‐Hui Zhao, Yue‐Tao Guo, Hong‐Li Zhang, Yuan‐Yuan Chen, Jing Lu, Xiao‐Peng Chen, Feng Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title | Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title_full | Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title_fullStr | Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title_full_unstemmed | Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title_short | Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio |
title_sort | therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: focus on influencing factors on the plasma concentration‐to‐dose ratio |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712465/ https://www.ncbi.nlm.nih.gov/pubmed/36177517 http://dx.doi.org/10.1002/epi4.12653 |
work_keys_str_mv | AT liyue therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT dongna therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT qinyuxin therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT daihaoran therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT huyahui therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT zhaoyuetao therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT guohongli therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT zhangyuanyuan therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT chenjing therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT luxiaopeng therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio AT chenfeng therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio |